How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Hyperammonemia Treatment Market
- By Treatment Type: Nitrogen Scavengers, Liver Dialysis, Enzyme Replacement Therapy, Gene Therapy, Dietary Management
- By Cause of Hyperammonemia: Urea Cycle Disorders, Liver Cirrhosis, Inborn Errors of Metabolism, Drug-Induced Hyperammonemia, Infections
- By Patient Type: Neonates, Pediatrics, Adults
- By Route of Administration: Oral, Intravenous, Intramuscular
- By End User: Hospitals, Specialty Clinics, Home Healthcare Settings
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Nitrogen Scavengers leads By Treatment Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 291 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.177 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.185 →
Full report · locked preview
Everything inside the Hyperammonemia Treatment Market report
A complete, evidence-based study - 12 chapters and 122 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Treatment Type 5
Cause of Hyperammonemia 5
Patient Type 3
Route of Administration 3
End User 3
Companies profiled
Horizon Therapeutics
Recordati Rare Diseases
Ammonul (Salix Pharmaceuticals
a Bausch Health company)
Orphan Europe (part of Recordati)
Sobi (Swedish Orphan Biovitrum)
Ultragenyx Pharmaceutical Inc.
Mallinckrodt Pharmaceuticals
Chiesi Farmaceutici
Mitsubishi Tanabe Pharma Corporation
MediGene AG
Neurocrine Biosciences
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Horizon Therapeutics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Recordati Rare Diseases
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Ammonul (Salix Pharmaceuticals
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →a Bausch Health company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Orphan Europe (part of Recordati)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Sobi (Swedish Orphan Biovitrum)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Ultragenyx Pharmaceutical Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Mallinckrodt Pharmaceuticals
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Chiesi Farmaceutici
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Mitsubishi Tanabe Pharma Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →MediGene AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Neurocrine Biosciences
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Baxter International Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Ferring Pharmaceuticals
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Ipsen
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$1,382M by 2033 · 6.5% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Nitrogen Scavengers48.3
- Liver Dialysis18.3
- Enzyme Replacement Therapy8.0
- Gene Therapy10.1
- Dietary Management15.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$274.8M → $451.1M · 6.4%
Europe$191.5M → $288.2M · 5.2%
Asia Pacific$174.9M → $274.5M · 5.8%
Latin America$108.2M → $199.4M · 7.9%
Middle East and Africa$83.3M → $149.1M · 7.6%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →6.502026
6.502027
6.522028
6.532029
6.532030
6.542031
6.572032
6.572033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Horizon Therapeutics28.9
- Recordati Rare Diseases11.2
- Ammonul (Salix Pharmaceuticals12.9
- a Bausch Health company)4.5
- Orphan Europe (part of Recordati)9.4
- Sobi (Swedish Orphan Biovitrum)5.1
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Treatment Type14.5%
Cause of Hyperammonemia17.8%
Patient Type24.0%
Route of Administration21.8%
End User22.0%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.1
- Europe21.2
- Asia Pacific20.1
- Latin America14.6
- Middle East and Africa10.9
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Horizon Therapeutics | 82 | 92 | 77 | 88 | 77 | 83 | 83 |
| Recordati Rare Diseases | 77 | 87 | 78 | 93 | 85 | 70 | 82 |
| Ammonul (Salix Pharmaceuticals | 86 | 71 | 80 | 69 | 70 | 79 | 76 |
| a Bausch Health company) | 64 | 79 | 65 | 79 | 63 | 82 | 72 |
| Orphan Europe (part of Recordati) | 74 | 67 | 51 | 62 | 73 | 57 | 64 |
| Sobi (Swedish Orphan Biovitrum) | 60 | 70 | 57 | 68 | 52 | 62 | 62 |
| Ultragenyx Pharmaceutical Inc. | 66 | 50 | 46 | 61 | 43 | 54 | 53 |
| Mallinckrodt Pharmaceuticals | 56 | 41 | 56 | 41 | 50 | 57 | 50 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Horizon Therapeutics
- Recordati Rare Diseases
- Ammonul (Salix Pharmaceuticals
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Horizon Therapeutics | ◐ | ✓ | ✓ | ◐ | ✓ | ◐ |
| Recordati Rare Diseases | ✓ | ✓ | ◐ | ✓ | ◐ | ◐ |
| Ammonul (Salix Pharmaceuticals | ✓ | − | ✓ | − | ◐ | ✓ |
| a Bausch Health company) | − | ✓ | ✓ | ✓ | − | ◐ |
| Orphan Europe (part of Recordati) | ◐ | ✓ | − | ◐ | ◐ | − |
| Sobi (Swedish Orphan Biovitrum) | − | ◐ | ◐ | − | ◐ | ◐ |
| Ultragenyx Pharmaceutical Inc. | ◐ | − | − | ◐ | − | − |
| Mallinckrodt Pharmaceuticals | ◐ | − | ◐ | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Horizon Therapeutics83
2Recordati Rare Diseases82
3Ammonul (Salix Pharmaceuticals76
4a Bausch Health company)72
5Orphan Europe (part of Recordati)64
6Sobi (Swedish Orphan Biovitrum)62
7Ultragenyx Pharmaceutical Inc.53
8Mallinckrodt Pharmaceuticals50
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Horizon TherapeuticsRecordati Rare Diseases
Challenger2
Strong scale, closing on the leaders.
Ammonul (Salix Pharmaceuticalsa Bausch Health company)
Contender2
Focused players with pockets of strength.
Orphan Europe (part of Recordati)Sobi (Swedish Orphan Biovitrum)
Niche2
Specialists in a single segment or region.
Ultragenyx Pharmaceutical Inc.Mallinckrodt Pharmaceuticals
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Treatment Type in North America, then scale across Hyperammonemia Treatment Market — a $155M beachhead inside a $2.74B market.
Beachhead (SOM)$155Mobtainable near-term
Serviceable (SAM)$1.04Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion92 fit
Nitrogen Scavengers
Best fit — highest urgency & budget in Treatment Type.
Economic buyer81 fit
Liver Dialysis
Strong fit — clear ROI and a fast path to value.
End user68 fit
Enzyme Replacement Therapy
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Treatment Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Cause of Hyperammonemia & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Patient Type
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales46%
Partner / channel28%
Digital / self-serve19%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Treatment Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Hyperammonemia Treatment Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified40%
Sales qualified23%
Evaluation12%
Closed-won7%
$18.5KCAC
$68KLTV
3.7:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Hyperammonemia Treatment Market is a resilient opportunity — $7.30B by 2033, compounding at 5.1%.
TAM · 2025$4.91Btoday
TAM · 2033$7.30Bforecast
CAGR5.1%2027–2033
Cumulative$54.3Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$7.30BTotal addressable market
SAM$2.69BServiceable available market
SOM$492MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →5.1% CAGR
Demand compounds through 2033, outpacing GDP across Treatment Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Treatment Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$7.30BLarge & growingTAM by 2033 at 5.1% CAGR
$2.69BServiceable nowreachable with today’s model
$492MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$5.69BBear3.3% CAGR
$7.30BBase5.1% CAGR
$9.34BBull6.7% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Cause of Hyperammonemia optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Hyperammonemia Treatment Market — a $1.29B market by 2033. Plan: grow share from 10.5% to 17.3%.
Market size · 2033$1.29Btotal addressable
Market CAGR3.4%2027–2033
Target share17.3%from 10.5% today
Revenue ambition$224Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.5% | 17.3% | On track |
| Revenue | $134M | $224M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Ahead |
| Gross margin | 28.2% | 38.7% | On track |
| Customer retention | 85.5% | 96.3% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Treatment Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Cause of Hyperammonemia capability
A defensible second engine — invest in Cause of Hyperammonemia to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Treatment Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Cause of Hyperammonemia
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $28M capacity & capability investment
- Greenlight bolt-on M&A in Cause of Hyperammonemia
- Authorise North America expansion plan
- Fund R&D program for Treatment Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossAt risk
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Hyperammonemia Treatment Market conversation — a $5.59B market you can size, segment and defend in minutes.
Market size · 2033$5.59Btotal opportunity
Growth10.8%CAGR to 2033
Addressable buyers1,464+accounts in scope
Typical ROI5.2×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Treatment Type
Goal Grow share in Treatment Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.2×return on cost, year one
< 2 mopayback period
$40K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Horizon TherapeuticsRecordati Rare DiseasesAmmonul (Salix Pharmaceuticalsa Bausch Health company)Orphan Europe (part of Recordati)Sobi (Swedish Orphan Biovitrum)Ultragenyx Pharmaceutical Inc.Mallinckrodt Pharmaceuticals+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Hyperammonemia Treatment Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Hyperammonemia Treatment Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Hyoscyamine Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportHyodeoxycholic Acid Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportHygromycin B Solution Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportHygromycin B Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportHygienic Weighing Equipment Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportAnti Radiation Clothing Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportAnti Radiation Vest Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportHygienic and Aseptic Valves for Pharmaceuticals and Biotechnology Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportHygiene Stations Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportHygiene and Healthcare Breathable Film Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportHydroxyzine Hydrochloride Market
Market size, share, segmentation and regional forecast.
$945M market · 2025 base year
View reportHydroxyvitamins Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.